Literature DB >> 20407032

Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo.

Amitava Sengupta1, Jorden Arnett, Susan Dunn, David A Williams, Jose A Cancelas.   

Abstract

Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease (MPD) initiated by p210-BCR-ABL-mediated transformation of hematopoietic stem cells (HSCs). Inhibition of the ABL kinase alone is not sufficient to eradicate leukemic stem cells (LSCs). We have previously shown that the deficiency of Rac2 GTPase signaling, but not Rac1, in p210-BCR-ABL-transduced hematopoietic cells prolonged survival of mice with MPD. Here we demonstrate that absence of Rac2 GTPase prolongs survival of HSC-initiated, inducible Scl/p210-BCR-ABL (Scl/p210) binary transgenic mice, it induces apoptosis, and, unlike in normal HSC and progenitor (HSC/P), impairs LSC and progenitor (LSC/P) proliferation in vivo. As a result, Rac2 deficiency causes functional exhaustion of the LSC pool in vivo. This defect is not due to impaired interaction with the hematopoietic microenvironment as reflected by its unaltered adhesion, migration, and homing to recipient organs. In summary, Rac2 deficiency exhausts the LSC pool in vivo through impairment of oncogene-induced proliferation and survival signals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20407032      PMCID: PMC2904584          DOI: 10.1182/blood-2009-10-247437

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

Authors:  Catriona H M Jamieson; Laurie E Ailles; Scott J Dylla; Manja Muijtjens; Carol Jones; James L Zehnder; Jason Gotlib; Kevin Li; Markus G Manz; Armand Keating; Charles L Sawyers; Irving L Weissman
Journal:  N Engl J Med       Date:  2004-08-12       Impact factor: 91.245

2.  BCR/ABL induces multiple abnormalities of cytoskeletal function.

Authors:  R Salgia; J L Li; D S Ewaniuk; W Pear; E Pisick; S A Burky; T Ernst; M Sattler; L B Chen; J D Griffin
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 3.  Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.

Authors:  Ruibao Ren
Journal:  Nat Rev Cancer       Date:  2005-03       Impact factor: 60.716

4.  BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

Authors:  Mirle Schemionek; Christian Elling; Ulrich Steidl; Nicole Bäumer; Ashley Hamilton; Tilmann Spieker; Joachim R Göthert; Martin Stehling; Amy Wagers; Claudia S Huettner; Daniel G Tenen; Lara Tickenbrock; Wolfgang E Berdel; Hubert Serve; Tessa L Holyoake; Carsten Müller-Tidow; Steffen Koschmieder
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

5.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

6.  Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense.

Authors:  A W Roberts; C Kim; L Zhen; J B Lowe; R Kapur; B Petryniak; A Spaetti; J D Pollock; J B Borneo; G B Bradford; S J Atkinson; M C Dinauer; D A Williams
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

7.  Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

Authors:  Steffen Koschmieder; Berthold Göttgens; Pu Zhang; Junko Iwasaki-Arai; Koichi Akashi; Jeffery L Kutok; Tajhal Dayaram; Kristin Geary; Anthony R Green; Daniel G Tenen; Claudia S Huettner
Journal:  Blood       Date:  2004-08-26       Impact factor: 22.113

8.  Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases.

Authors:  Yi Gu; Marie-Dominique Filippi; Jose A Cancelas; Jamie E Siefring; Emily P Williams; Aparna C Jasti; Chad E Harris; Andrew W Lee; Rethinasamy Prabhakar; Simon J Atkinson; David J Kwiatkowski; David A Williams
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

9.  Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.

Authors:  Scott C Kogan; Jerrold M Ward; Miriam R Anver; Jules J Berman; Cory Brayton; Robert D Cardiff; John S Carter; Sherri de Coronado; James R Downing; Torgny N Fredrickson; Diana C Haines; Alan W Harris; Nancy Lee Harris; Hiroshi Hiai; Elaine S Jaffe; Ian C M MacLennan; Pier Paolo Pandolfi; Paul K Pattengale; Archibald S Perkins; R Mark Simpson; Mark S Tuttle; Joanne F Wong; Herbert C Morse
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

10.  Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL.

Authors:  R A Shivdasani; E L Mayer; S H Orkin
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

View more
  30 in total

Review 1.  Cancer stem cells: a stride towards cancer cure?

Authors:  Amitava Sengupta; Jose A Cancelas
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

2.  Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia.

Authors:  Yin Xiao; Hui-hua Hu; Hong-xiang Wang; Xiao-jian Zhu; Ping Zou; Zhi-chao Chen; Zhao-dong Zhong; Wei-ming Li; Yong You
Journal:  Acta Pharmacol Sin       Date:  2012-06-11       Impact factor: 6.150

3.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Authors:  Paolo Neviani; Jason G Harb; Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Justin J Ellis; Gregory Ferenchak; Adrienne M Dorrance; Carolyn A Paisie; Anna M Eiring; Yihui Ma; Hsiaoyin C Mao; Bin Zhang; Mark Wunderlich; Philippa C May; Chaode Sun; Sahar A Saddoughi; Jacek Bielawski; William Blum; Rebecca B Klisovic; Janelle A Solt; John C Byrd; Stefano Volinia; Jorge Cortes; Claudia S Huettner; Steffen Koschmieder; Tessa L Holyoake; Steven Devine; Michael A Caligiuri; Carlo M Croce; Ramiro Garzon; Besim Ogretmen; Ralph B Arlinghaus; Ching-Shih Chen; Robert Bittman; Peter Hokland; Denis-Claude Roy; Dragana Milojkovic; Jane Apperley; John M Goldman; Alistair Reid; James C Mulloy; Ravi Bhatia; Guido Marcucci; Danilo Perrotti
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

4.  Atypical protein kinase C (aPKCzeta and aPKClambda) is dispensable for mammalian hematopoietic stem cell activity and blood formation.

Authors:  Amitava Sengupta; Angeles Duran; Eri Ishikawa; Maria Carolina Florian; Susan K Dunn; Ashley M Ficker; Michael Leitges; Hartmut Geiger; Maria Diaz-Meco; Jorge Moscat; Jose A Cancelas
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-08       Impact factor: 11.205

5.  Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.

Authors:  Benjamin Mizukawa; Junping Wei; Mahesh Shrestha; Mark Wunderlich; Fu-Sheng Chou; Andrea Griesinger; Chad E Harris; Ashish R Kumar; Yi Zheng; David A Williams; James C Mulloy
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

6.  Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiation.

Authors:  Yi Zeng; Hal E Broxmeyer; Karl Staser; Brahmananda Reddy Chitteti; Su-Jung Park; Seongmin Hahn; Scott Cooper; Zejin Sun; Li Jiang; XianLin Yang; Jin Yuan; Rachelle Kosoff; George Sandusky; Edward F Srour; Jonathan Chernoff; D Wade Clapp
Journal:  Stem Cells       Date:  2015-05       Impact factor: 6.277

7.  Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.

Authors:  Amitava Sengupta; Ashley M Ficker; Susan K Dunn; Malav Madhu; Jose A Cancelas
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

8.  8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation.

Authors:  Bo Jiao; Zhi-Hong Ren; Ping Liu; Li-Juan Chen; Jing-Yi Shi; Ying Dong; Julien Ablain; Lin Shi; Li Gao; Jun-Pei Hu; Rui-Bao Ren; Hugues de Thé; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 9.  New strategies to treat AML: novel insights into AML survival pathways and combination therapies.

Authors:  Ramya Nair; Alejandro Salinas-Illarena; Hanna-Mari Baldauf
Journal:  Leukemia       Date:  2020-10-29       Impact factor: 11.528

10.  Activation of the vascular niche supports leukemic progression and resistance to chemotherapy.

Authors:  Michael G Poulos; Eric J Gars; Michael C Gutkin; Christopher C Kloss; Michael Ginsberg; Joseph M Scandura; Shahin Rafii; Jason M Butler
Journal:  Exp Hematol       Date:  2014-08-29       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.